Skip to content
Call Us Today! 212-533-4646 | MON-FRI 12PM - 4PM (EST)
DONATE
SUBSCRIBE
Search for:
About Us
UNWLA 100
Publications
FAQ
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Initiatives
Advocate
Educate
Cultivate
Care
News
Newsletters
Sign Up For Our Newsletter
Join UNWLA
Become a Member
Volunteer With Us
Donate to UNWLA
Members Portal
Shop to Support Ukraine
Search for:
Print
Print Page
Download
Download Page
Download Right Page
Open
1
2-3
4-5
6-7
8-9
10-11
12-13
14-15
16-17
18-19
20-21
22-23
24-25
26-27
28-29
30-31
32-33
34-35
36-37
38-39
40
НАШЕ ЖИТТЯ • Серпень 2025 39 OUR HEALTH Ihor Magun, MD, FACP One of the hottest topics today is the new successful approach to weight loss using GLP-1 medica - tions. These medications elimi - nate the need for extreme diet - ing or willpower to lose weight. Their mechanism of action is more aligned with the body’s natural processes, thereby pro - moting a sustainable option for weight control. The New Weight Loss Medications GLP-1 glucagon-like peptide-1 is a hormone that stimulates the pancreas to produce more insu - lin after a meal, slows down the passage of food from the stom - ach, and acts in the brain to re - duce hunger. Since the passage of food in the stomach is slowed down, one feels “full” sooner and consequently eats less. There are several GLP-1 med - ications in the market, but only three medications are approved for weight loss: Wegovy, Sax - enda, and Zepbound. The oth - er medications — Ozempic, Rybelsus, Victoza, Mounjaro, Trulicity, Byetta, and Bydure - on — are approved for diabetes but do have weight-reducing properties. Dosages for weight loss are typically higher than the same drug taken to manage di - abetes. The drugs’ efficacy varies from person to person. Many factors play a role in a response, includ - ing underlying health issues, life - style, and genetics. If one GLP-1 drug isn’t successful or tolerated, one may be able to try another. GLP-1 medications have been used to treat diabetes for about two decades, but more recent - ly there has been approval for weight loss in individuals with obesity with a body mass index (BMI) of 30 or greater. Although these drugs have had extensive clinical testing, com - mon side effects include nausea, constipation, and diarrhea, all of which typically subside with time. To limit the side effects, the medications are dosed at a lower dose and progressively ti - trated to a higher dose as side effects are minimal and efficacy is increased. The benefits of weight loss (outside of the obvious and blood glucose control) have shown im - provement in cognition and im - proved cardiovascular disease — in those individuals who present with these underlying issues. Individuals with a history of gallbladder disease, pancreatitis, medullary thyroid cancer, para - thyroid or adrenal cancer should not be prescribed this class of medication. Many factors influence weight loss with GLP-1 medications. These include the actual dosage of the medication, lifestyle, and obviously paying attention to the type of food selected to be eaten. Cost is a major issue, and not all insurance companies cover the high price. GLP-1 are not miracle drugs, but when incorporated in the motivated individual, they will make a significant impact on both the physical and overall well-being.
Page load link
Go to Top
1 
2-3 
4-5 
6-7 
8-9 
10-11 
12-13 
14-15 
16-17 
18-19 
20-21 
22-23 
24-25 
26-27 
28-29 
30-31 
32-33 
34-35 
36-37 
38-39 
40 
